Search Results - "Koopman, Miriam"

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database by Franko, Jan, Dr, Shi, Qian, PhD, Meyers, Jeffrey P, PhD, Maughan, Timothy S, Prof, Adams, Richard A, Prof, Seymour, Matthew T, Prof, Saltz, Leonard, Prof, Punt, Cornelis J A, Prof, Koopman, Miriam, MD, Tournigand, Christophe, Prof, Tebbutt, Niall C, Prof, Diaz-Rubio, Eduardo, Prof, Souglakos, John, MD, Falcone, Alfredo, Prof, Chibaudel, Benoist, MD, Heinemann, Volker, Prof, Moen, Joseph, MS, De Gramont, Aimery, Prof, Sargent, Daniel J, Prof, Grothey, Axel, Prof

“…Summary Background Patients with peritoneal metastatic colorectal cancer have reduced overall survival compared with patients with metastatic colorectal cancer…”
Get full text

Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies by Venderbosch, Sabine, Nagtegaal, Iris D, Maughan, Tim S, Smith, Christopher G, Cheadle, Jeremy P, Fisher, David, Kaplan, Richard, Quirke, Philip, Seymour, Matthew T, Richman, Susan D, Meijer, Gerrit A, Ylstra, Bauke, Heideman, Danielle A M, de Haan, Anton F J, Punt, Cornelis J A, Koopman, Miriam

“…To determine the prevalence and prognostic value of mismatch repair (MMR) status and its relation to BRAF mutation (BRAF(MT)) status in metastatic colorectal…”
Get full text

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data by Meulendijks, Didier, PharmD, Henricks, Linda M, PharmD, Sonke, Gabe S, MD, Deenen, Maarten J, PhD, Froehlich, Tanja K, PhD, Amstutz, Ursula, PhD, Largiadèr, Carlo R, Prof, Jennings, Barbara A, PhD, Marinaki, Anthony M, PhD, Sanderson, Jeremy D, MD, Kleibl, Zdenek, PhD, Kleiblova, Petra, PhD, Schwab, Matthias, Prof, Zanger, Ulrich M, Prof, Palles, Claire, PhD, Tomlinson, Ian, Prof, Gross, Eva, PhD, van Kuilenburg, André B P, PhD, Punt, Cornelis J A, Prof, Koopman, Miriam, MD, Beijnen, Jos H, Prof, Cats, Annemieke, MD, Schellens, Jan H M, Prof

“…Summary Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine dehydrogenase (DPD) deficiency, which can result from…”
Get full text

Patient-derived organoids as a predictive biomarker for treatment response in cancer patients by Wensink, G. Emerens, Elias, Sjoerd G., Mullenders, Jasper, Koopman, Miriam, Boj, Sylvia F., Kranenburg, Onno W., Roodhart, Jeanine M. L.

“…Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing…”
Get full text

Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry by Trinh, Anne, Trumpi, Kari, De Sousa E Melo, Felipe, Wang, Xin, de Jong, Joan H, Fessler, Evelyn, Kuppen, Peter J K, Reimers, Marlies S, Swets, Marloes, Koopman, Miriam, Nagtegaal, Iris D, Jansen, Marnix, Hooijer, Gerrit K J, Offerhaus, George J A, Kranenburg, Onno, Punt, Cornelis J, Medema, Jan Paul, Markowetz, Florian, Vermeulen, Louis

“…Recent transcriptomic analyses have identified four distinct molecular subtypes of colorectal cancer with evident clinical relevance. However, the requirement…”
Get full text

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer by Tol, Jolien, Koopman, Miriam, Cats, Annemieke, Rodenburg, Cees J, Creemers, Geert J.M, Schrama, Jolanda G, Erdkamp, Frans L.G, Vos, Allert H, van Groeningen, Cees J, Sinnige, Harm A.M, Richel, Dirk J, Voest, Emile E, Dijkstra, Jeroen R, Vink-Börger, Marianne E, Antonini, Ninja F, Mol, Linda, van Krieken, Johan H.J.M, Dalesio, Otilia, Punt, Cornelis J.A

“…Capecitabine, oxaliplatin, and bevacizumab are standard treatment for metastatic colorectal cancer. This trial tested whether adding cetuximab to this…”
Get full text

The Trial within Cohorts (TwiCs) study design in oncology: experience and methodological reflections by Kessels, Rob, May, Anne M, Koopman, Miriam, Roes, Kit C B

“…A Trial within Cohorts (TwiCs) study design is a trial design that uses the infrastructure of an observational cohort study to initiate a randomized trial…”
Get full text

Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer by Ketzer, Sander, Schimmel, Kirsten, Koopman, Miriam, Guchelaar, Henk-Jan

“…Despite progress in the treatment of metastatic colorectal cancer (mCRC) in the last 15 years, it is still a condition with a relatively low 5-year survival…”
Get full text

Management of cytotoxic chemotherapy-induced hand-foot syndrome by Kwakman, Johannes J M, Elshot, Yannick S, Punt, Cornelis J A, Koopman, Miriam

“…Improvements in systemic cancer treatments have resulted in more patients surviving for prolonged periods of time on treatment. This has made treatment-related…”
Get full text

The Impact of Primary Tumor Location in Synchronous Metastatic Colorectal Cancer: Differences in Metastatic Sites and Survival by Brouwer, Nelleke P. M., van der Kruijssen, Dave E. W., Hugen, Niek, de Hingh, Ignace H. J. T., Nagtegaal, Iris D., Verhoeven, Rob H. A., Koopman, Miriam, de Wilt, Johannes H. W.

“…Purpose We explored differences in survival between primary tumor locations, hereby focusing on the role of metastatic sites in synchronous metastatic…”
Get full text

Effects of an Exercise Program in Colon Cancer Patients undergoing Chemotherapy by VAN VULPEN, JONNA K, VELTHUIS, MIRANDA J, STEINS BISSCHOP, CHARLOTTE N, TRAVIER, NOÉMIE, VAN DEN BUIJS, BRAM J W, BACKX, FRANK J G, LOS, MAARTJE, ERDKAMP, FRANS L G, BLOEMENDAL, HAIKO J, KOOPMAN, MIRIAM, DE ROOS, MARNIX A J, VERHAAR, MARLIES J, TEN BOKKEL-HUININK, DAAN, VAN DER WALL, ELSKEN, PEETERS, PETRA H M, MAY, ANNE M

“…PURPOSEFatigue is a common problem among colon cancer patients and typically increases during chemotherapy. Exercise during chemotherapy might have beneficial…”
Get full text

Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models by Degeling, Koen, IJzerman, Maarten J, Koopman, Miriam, Koffijberg, Hendrik

“…Parametric distributions based on individual patient data can be used to represent both stochastic and parameter uncertainty. Although general guidance is…”
Get full text

Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients by Kurk, Sophie, Peeters, Petra, Stellato, Rebecca, Dorresteijn, B., Jong, Pim, Jourdan, Marion, Creemers, Geert‐Jan, Erdkamp, Frans, Jongh, Felix, Kint, Peter, Simkens, Lieke, Tanis, Bea, Tjin‐A‐Ton, Manuel, Van Der Velden, Ankie, Punt, Cornelis, Koopman, Miriam, May, Anne

“…Background Increasing evidence suggests that severe skeletal muscle index (SMI) loss (sarcopenia) is associated with poor overall survival in metastatic…”
Get full text

Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy by Smeets, Dominiek, Miller, Ian S., O’Connor, Darran P., Das, Sudipto, Moran, Bruce, Boeckx, Bram, Gaiser, Timo, Betge, Johannes, Barat, Ana, Klinger, Rut, van Grieken, Nicole C. T., Cremolini, Chiara, Prenen, Hans, Mazzone, Massimiliano, Depreeuw, Jeroen, Bacon, Orna, Fender, Bozena, Brady, Joseph, Hennessy, Bryan T., McNamara, Deborah A., Kay, Elaine, Verheul, Henk M., Maarten, Neerincx, Gallagher, William M., Murphy, Verena, Prehn, Jochen H. M., Koopman, Miriam, Punt, Cornelis J. A., Loupakis, Fotios, Ebert, Matthias P. A., Ylstra, Bauke, Lambrechts, Diether, Byrne, Annette T.

“…Increased copy number alterations (CNAs) indicative of chromosomal instability (CIN) have been associated with poor cancer outcome. Here, we study CNAs as…”
Get full text

Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial by Koopman, Miriam, MD, Antonini, Ninja F, MSc, Douma, Joep, MD, Wals, Jaap, MD, Honkoop, Aafke H, MD, Erdkamp, Frans LG, MD, de Jong, Robert S, MD, Rodenburg, Cees J, MD, Vreugdenhil, Gerard, MD, Loosveld, Olaf JL, MD, van Bochove, Aart, MD, Sinnige, Harm AM, MD, Creemers, Geert-Jan M, MD, Tesselaar, Margot ET, MD, Slee, Peter H Th J, MD, Werter, Marjon JBP, MD, Mol, Linda, Msc, Dalesio, Otilia, MSc, Punt, Cornelis JA, Prof

“…Summary Background The optimum use of cytotoxic drugs for advanced colorectal cancer has not been defined. Our aim was to investigate whether combination…”
Get full text

Management of liver metastases in colorectal cancer patients: A retrospective case-control study of systemic therapy versus liver resection by de Ridder, Jannemarie A.M, van der Stok, Eric P, Mekenkamp, Leonie J, Wiering, Bastiaan, Koopman, Miriam, Punt, Cornelis J.A, Verhoef, Cornelis, de Wilt, Johannes H

“…Abstract Objective To evaluate and compare the overall survival (OS) in case-matched patient groups treated either with systemic therapy or surgery for…”
Get full text

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology by Goldberg, Richard M, Adams, Richard, Buyse, Marc, Eng, Cathy, Grothey, Axel, André, Thierry, Sobrero, Alberto F, Lichtman, Stuart M, Benson, Al B, Punt, Cornelis J A, Maughan, Tim, Burzykowski, Tomasz, Sommeijer, Dirkje, Saad, Everardo D, Shi, Qian, Coart, Elisabeth, Chibaudel, Benoist, Koopman, Miriam, Schmoll, Hans-Joachim, Yoshino, Takayuki, Taieb, Julien, Tebbutt, Niall C, Zalcberg, John, Tabernero, Josep, Van Cutsem, Eric, Matheson, Alastair, de Gramont, Aimery

“…Abstract Meta-analysis based on individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from…”
Get full text

Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice by Küçükköse, Emre, Heesters, Balthasar A, Villaudy, Julien, Verheem, André, Cercel, Madalina, van Hal, Susan, Boj, Sylvia F, Borel Rinkes, Inne H M, Punt, Cornelis J A, Roodhart, Jeanine M L, Laoukili, Jamila, Koopman, Miriam, Spits, Hergen, Kranenburg, Onno

“…BackgroundThe immunogenic nature of metastatic colorectal cancer (CRC) with high microsatellite instability (MSI-H) underlies their responsiveness to immune…”
Get full text

Survival after associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for advanced colorectal liver metastases: A case-matched comparison with palliative systemic therapy by Olthof, Pim B., MD, Huiskens, Joost, MD, Wicherts, Dennis A., MD, PhD, Huespe, Pablo E., MD, Ardiles, Victoria, MD, Robles-Campos, Ricardo, MD, PhD, Adam, René, MD, PhD, Linecker, Michael, MD, Clavien, Pierre-Alain, MD, PhD, Koopman, Miriam, MD, PhD, Verhoef, Cornelis, MD, PhD, Punt, Cornelis J.A., MD, PhD, van Gulik, Thomas M., MD, PhD, de Santibanes, Eduardo, MD, PhD

“…Background Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) allows the resection of colorectal liver metastases with…”
Get full text

Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients by Kurk, Sophie A., Peeters, Petra H.M., Dorresteijn, Bram, Jong, Pim A., Jourdan, Marion, Kuijf, Hugo J., Punt, Cornelis J.A., Koopman, Miriam, May, Anne M.

“…Background Observational studies suggest that loss of skeletal muscle mass (SMM) is associated with chemotherapy‐related toxicity, poor quality of life, and…”
Get full text